Accepted for Publication: February 12, 2015.
Published Online: April 13, 2015. doi:10.1001/jamaneurol.2015.0202.
Study concept and design: Tarawneh, Head, Buckles, Fagan, Ladenson, Morris, Holtzman.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Tarawneh, Holtzman.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Tarawneh.
Obtained funding: Fagan, Ladenson, Morris, Holtzman.
Administrative, technical, or material support: Ladenson, Morris, Holtzman.
Conflict of Interest Disclosures: Dr Fagan reported serving on the scientific advisory boards of IBL International and Roche and reported being a consultant for AbbVie. Dr Holtzman reported being a cofounder of and on the scientific advisory board for C2N Diagnostics and reported serving as a consultant for Genentech, AstraZeneca, and NeuroPhage. No other disclosures were reported.
Funding/Support: This work was supported by grants P50-AG05681, P01-AG03991, and P01-AG026276 from the National Institutes of Health (Dr Morris); by Eli Lilly and Company (Dr Holtzman); by The JPB Foundation (Dr Holtzman); by Siemens Healthcare Diagnostics (Dr Ladenson); and by The Charles F. and Joanne Knight Alzheimer’s Disease Research Center.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge the contributions of Kim Lipsey and the Clinical, Psychometrics, Biomarker, Imaging, and Biostatistics cores of The Charles F. and Joanne Knight Alzheimer’s Disease Research Center.